Median DOR of 44.3 months supports durability of response 4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survival Long-term survival of 42+ - 60+ months observed among complete responders Oct. 23, 2026 -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox® platform-based photoimmunotherapy, today announced the presentation of long-term follow-up results from the Phase 1b/2 ASP-1929-181 study (NCT0430579

Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient (pMMR) metastatic colorectal cancer EO4010 was well tolerated and expanded tumor-targeting CD8 T cells in most patients, with expansion detectable after two to three administrations Association between CD8 T-cell expansion and clinical outcome, previously reported for EO2463 in lymphoma, now also observed with EO4010 in a solid tumor Data to be prese

Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN-016 October 23, 2026 — Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors. The c

South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene’s investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m). The financial package includes an upfront payment alongside milestone payments tied to specific development, regulatory, and commercial targets. Royalties on net sales remain separate from the package. Kaigene also retains an option to co-market the candidate in South Korea under th

BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care 24% objective response rate (8 of 34 evaluable patients: 1 complete and 7 partial responses), including patients with high-grade serous and clear cell carcinoma53% disease control rate, with several patients in stable disease beyond 10 months; 6 patients were still on treatment at data cutoffMedian progression-free su

October 27, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for VEOZA™ (fezolinetant 45 mg) seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, commonly known as hot flashes and night sweats, are among the most common symptoms associated w

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China Oct. 22, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that the National Medical Products Administration (NMPA) of China has approved the Biologics License Application (BLA) for batoclimab injection (subcutaneous inj

EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial The data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings October 23, 2026

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment Competitive safety pro no significant off-target t

Gilead Sciences waded further into the immunology and inflammation (I&I) disease space on Thursday with the proposed purchase of PepStar Therapeutics' IL-23R inhibitor programme, which includes lead candidate HCXT-2001, in Phase I testing. The US drugmaker is splashing $1.28 billion in upfront cash to gain the asset, an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life. The acquisition is expected to close this quarter. According to Gilead, IL-23R is a clinically validated